Novo Nordisk Teams With Deep Apple On Non-Incretin Obesity Approach

 
• By Joseph Haas
  
In its latest cardiometabolic deal, Novo Nordisk will partner with Deep Apple (Shutterstock)

More from Deals

More from Therapy Areas